Characteristics and prognosis in adult patients with early T-cell precursor acute lymphoblastic leukemia.
10.3760/cma.j.issn.0253-2727.2018.12.002
- Author:
Xiao Yuan GONG
1
;
Ying WANG
;
Bing Cheng LIU
;
Hui WEI
;
Chun Lin ZHOU
;
Dong LIN
;
Kai Qi LIU
;
Shu Ning WEI
;
Ben Fa GONG
;
Guang Ji ZHANG
;
Yun Tao LIU
;
Xing Li ZHAO
;
Yan LI
;
Run Xia GU
;
Shao Wei QIU
;
Ying Chang MI
;
Jian Xiang WANG
Author Information
1. State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China.
- Publication Type:Journal Article
- Keywords:
Adult;
Leukemia, T lymphocyte, acute;
Prognosis
- MeSH:
Adolescent;
Adult;
China;
Disease-Free Survival;
Female;
Humans;
Male;
Middle Aged;
Precursor Cells, T-Lymphoid;
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma;
Prognosis;
Remission Induction;
Retrospective Studies;
Young Adult
- From:
Chinese Journal of Hematology
2018;39(12):977-982
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To analyze the clinical, laboratory characteristics and prognosis of adult early T-cell precursor acute lymphoblastic leukemia (ETP-ALL). Methods: The clinical data of 13 adult ETP-ALL patients from January 2009 to March 2017 were retrospectively analyzed and compared with non-ETP ALL patients. Results: 13 ETP-ALL patients (17.3%) were identified in 75 adult T-ALL patients, the median age of the patients was 35 years old (15 to 49 years) and 10 patients were male (76.9%). ETP-ALL patients had lower WBC count, LDH level, blasts in peripheral blood, lower incidence of thymic mass and higher PLT count compared to non-ETP ALL patients. The CR rate after one course induction chemotherapy for ETP-ALL and non-ETP ALL patients was 33.3% and 90.1%, respectively (χ(2)=26.521, P<0.001). The median overall survival(OS) was 11.33 (95%CI 0-28.46) and 25.69 (95%CI 11.98-39.41) months, respectively. The 3-year OS was 41.7% and 40.7%, respectively (P=0.699). The median event free survival (EFS) was 1.51 (95%CI 1.23-1.79) and 21.36 (95%CI 4.67-38.04) months, respectively. The 3-year EFS was 16.7% and 39.5%, respectively (P=0.002). The 3-year relapse free survival (RFS) was 53.0% and 52.0%, respectively (P=0.797). Multivariate analysis revealed that CNSL and allo-HSCT were independent risk factors affecting OS of T-ALL and ETP-ALL didn't affect the prognosis of T-ALL. Conclusion: To our knowledge, this study is the first report on characteristics and prognosis of adult ETP-ALL patients in China. At total of 13 T-ALL patients (17.3%) were classified as having ETP-ALL. These patients had a lower leukemia burden and lower CR rate after one course induction compared to non-ETP ALL patients. Allo-HSCT can improve the prognosis of ETP-ALL.
